Skip to Main Content Menu Search Site
Technologies / Therapeutics

Therapeutics

We are taking a multipronged approach to advance therapeutics discovery and development, including the use of predictive bioanalytics, machine learning, and synthetic biology, as well as powerful new Organ Chip models of human diseases and drug safety and efficacy responses.

Opportunity Type:

MRBL: Next-Generation Gene Therapy for Molecular Skin Rejuvenation
MRBL: Next-Generation Gene Therapy for Molecular Skin Rejuvenation

The next-generation gene therapy for molecular skin rejuvenation combines a comprehensive target gene prediction with a novel transdermal delivery approach for therapeutic adenovirus-associated viruses. The platform targets monogenic disease indications in the skin, and extends the same targets to the treatment of common skin aging conditions.

Broad-Spectrum RNA Therapeutic for COVID-19 and Influenza
Broad-Spectrum RNA Therapeutic for COVID-19 and Influenza

The COVID-19 pandemic has killed more than two million people worldwide and death tolls continue to mount due to the lack of an effective prevention, cure, or widespread vaccine for the disease. Influenza viruses have been even more deadly in the past, and still cause hundreds of thousands of deaths every year. Seasonal flu vaccines...

Cellular “Backpacks” to Slow Tumor Growth
Cellular “Backpacks” to Slow Tumor Growth

Macrophages are the body’s multipurpose defense agents, patrolling for pathogens and engulfing cellular debris, foreign substances, microbes, and even cancer cells. But cancerous tumors have evolved an insidious defense mechanism: they can switch arriving macrophages from an anti-cancer state to a pro-cancer state, in which they help promote the tumor’s growth. As a result, attempts...

DNA Nanotechnology Tools: From Design to Applications
DNA Nanotechnology Tools: From Design to Applications

DNA nanostructures with their potential for cell and tissue permeability, biocompatibility, and high programmability at the nanoscale level are promising candidates as new types of drug delivery vehicles, highly specific diagnostic devices, and tools to decipher how biomolecules dynamically change their shapes, and interact with each other and with candidate drugs. Wyss Institute researchers are...

OMNIVAX: Broadly Deployable Infection Vaccine Platform
OMNIVAX: Broadly Deployable Infection Vaccine Platform

OMNIVAX is an immuno-material-based vaccine platform technology able to create safe and effective therapeutic and prophylactic vaccines against viral and bacterial threats. Its modular approach enables the rapid creation of vaccines for pathogens using known and unknown antigens. Current approaches include vaccines against some viral diseases.

Bone Marrow-Like Scaffolds for Accelerating Immune Reconstitution
Bone Marrow-Like Scaffolds for Accelerating Immune Reconstitution

An implantable bone marrow cryogel to accelerate the full reconstitution of the immune system, including T cell immunity, in patients that received chemotherapy and a bone marrow transplant. This could provide an off-the-shelf, material-based solution for patients with severe blood disorders whose immunity is recovering only slowly after treatment.

Regenerating Tissues with Sustained Growth Factor Delivery
Regenerating Tissues with Sustained Growth Factor Delivery

Millions of people worldwide suffer from traumatic injuries or health conditions that cause damage to soft tissues including nerves, muscles, and blood vessels. The body can heal some of that damage, but more serious cases like the severing of a nerve or sustained oxygen deprivation can lead to permanent loss of movement or sensation in...

Using Systems Biology to Find and Test New Drugs Faster
Using Systems Biology to Find and Test New Drugs Faster

The pharmaceutical industry is infamous for big numbers: it takes 10-15 years and can cost over $2 billion to bring a new drug from the lab to the market. Up to 6 of those years and $1 billion are spent in laborious preclinical trials to identify and validate new potential drug compounds, and much of...

eRNA: Controlled Enzymatic RNA Oligonucleotide Synthesis
eRNA: Controlled Enzymatic RNA Oligonucleotide Synthesis

Synthetic RNA oligonucleotides designed as specific successions of the four nucleobases A, U, G, and C that mimic naturally occurring RNA species are the key components of diverse RNA-based therapies. These include RNA therapeutics that can partially or completely turn off the expression of disease-causing genes (antisense and interfering RNAs), help replace or supplement dysfunctional...

1 snap 2
Single-Cell Encapsulation for Improved Cell Therapies

Mesenchymal stromal cells (MSCs) are valued for their ability to secrete compounds that modulate the body’s immune system, making them an attractive solution for existing problems with cell therapies including host-vs-graft disease and organ transplant rejections. However, MSCs are rapidly cleared from the body and can come under fire from the immune system. Efforts to...

Injectable Alginate Hydrogels for Medical Applications
Injectable Alginate Hydrogels for Medical Applications

One of the biggest challenges in medicine is getting a drug to the right part of the body at the right time. Even when the target site in the body is known, like a pain-causing injury or a cancerous tumor, most drugs are given as oral pills or intravenous infusions, which limits their effectiveness. In...

CogniXense: Target-Agnostic Drug Repurposing in Record Time
CogniXense: Target-Agnostic Drug Repurposing in Record Time

The problem There are more than 7,000 known rare genetic diseases that collectively afflict more patients in the United States than diabetes, but only 5% of these diseases have any effective treatment. A major driver of this lack of therapies is that about 75% of rare genetic diseases cause cognitive and behavioral impairment, which are...

Biomaterial Scaffolds for T Cell Expansion
Biomaterial Scaffolds for T Cell Expansion

Immunotherapy, or tweaking the body’s own immune system to treat disease, is attracting significant attention in the medical field for its potential to offer long-lasting cures with fewer side effects than chemotherapy or other drugs. One type of immunotherapy involves isolating T cells (a type of white blood cell) from a patient’s body, sometimes modifying...

Toehold Switches for Synthetic Biology
Toehold Switches for Synthetic Biology

The burgeoning field of synthetic biology is designing artificial gene circuits that recognize molecules in their environment and respond by regulating genes with desired activities. In the future, such capabilities could allow the engineering of cells as diagnostic or therapeutic devices, factories for the production of clinically or industrially coveted molecules, and as specialized devices...

Engineered Brain Organoids
Engineered Brain Organoids

The ability to derive and manipulate pluripotent stem cells has opened up new avenues for modeling biological systems in both healthy and diseased conditions. In order to more fully recapitulate the tissue microenvironment with its cell-cell, cell-extracellular matrix, and cell-niche interactions, it is essential to transition stem-cell culturing from monolayers to 3D structures. Self-organization of...

Microfluidic Drug Encapsulation
Microfluidic Drug Encapsulation

Because of their large molecular sizes and properties, biologic drugs, be it in the form of monoclonal antibodies that target disease-associated molecules or active proteins and enzymes that may correct deficiencies in the human body, have proven difficult to deploy in many cases. Their therapeutic effects on target cells and tissues often require high and...

Fusion Proteins for Reduced Drug Toxicity
Fusion Proteins for Reduced Drug Toxicity

Therapeutic variants of the natural hormone erythropoietin (EPO) which is produced in the kidney to boost the production of red blood cells are commonly used to treat anemias stemming from kidney disease, chemotherapy and other complications. However, many drugs that are based on therapeutic proteins, including EPO, often cause unwanted side effects because they not...

Cell-Free Biomolecule Manufacturing
Cell-Free Biomolecule Manufacturing

Wyss Institute researchers have developed a biomolecular manufacturing method that can quickly and easily produce a wide range of vaccines, antimicrobial peptides and antibody conjugates while doing so anywhere, even in places without access to electrical power or refrigeration. The breakthrough could provide a life-saving workaround for making modern interventions available in remote areas. Today...

DNA Nanostructures for Drug Delivery
DNA Nanostructures for Drug Delivery

Researchers at the Wyss Institute have developed two methods for building arbitrarily shaped nanostructures using DNA, with a focus on translating the technology towards nanofabrication and drug delivery applications. One proprietary nanofabrication technique, called “DNA-brick self-assembly,” uses short, synthetic strands of DNA that work like interlocking Lego® bricks. It capitalizes on the ability to program...

NanoRx: Mechanically-Activated Drug Targeting
NanoRx: Mechanically-Activated Drug Targeting

The Wyss team has developed a novel drug targeting nanotechnology that is activated locally by mechanical forces, either endogenous high shear stresses in blood created by vascular occlusion or mechanical energy applied locally using low-energy ultrasound radiation. Today, vascular blockage is the leading cause of death and disability in United States and Europe. Current therapies...

3D Bioprinting of Living Tissues
3D Bioprinting of Living Tissues

Progress in drug testing and regenerative medicine could greatly benefit from laboratory-engineered human tissues built of a variety of cell types with precise 3D architecture. But production of greater than millimeter sized human tissues has been limited by a lack of methods for building tissues with embedded life-sustaining vascular networks. In this video, the Wyss...

Close menu